ABC 120mg / 3TC 60mg, disp. and break. tab.

STD DORAABLA3TD

Valid Article

Former Code(s): DORAABLA3T-

Article is intended to be used with children (<12 years) ONLY.
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR02
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://msf.oodin.sh/web/image/product.template/571920/image_1920?unique=50168a3

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

ABACAVIR (ABC) / LAMIVUDINE (3TC)

Therapeutic Action

Fixed-dose combination (FDC) of two antiretrovirals, nucleoside reverse transcriptase inhibitors (NRTI)

Indications

HIV infection, in combination with other antiretrovirals

Instructions for use

The ABC 120mg/3TC 60mg dispersible, breakable tablets (scored for 1/2 or 1/4 dosing) are intended for paediatric use.

The dispersible tablet, breakable in 1/4 (DORAABLA3TD4) is intended for neonates aged 0 to 4 weeks who require ART or PNP (Post-Natal Prophylaxis):

  • neonates < 2 weeks old: 1/4 tablet every other day
  • neonates ≥ 2 weeks old: 1/4 tablet every day

Storage

Below 25°C